July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
High throughput screening for bioactive compound discovery
Author Affiliations & Notes
  • Timothy W Corson
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Timothy Corson, US 2016/0060241 A1, US 2016/0222388 A1, PCT/US2016/062851 (P)
  • Footnotes
    Support  NIH/NEI R01EY025641; BrightFocus Foundation; Retina Research Foundation; Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2580. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Timothy W Corson; High throughput screening for bioactive compound discovery. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2580. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Small molecules can be powerful probes for biological pathways and potential therapeutic leads. High throughput screening offers potential for identifying compounds with desired bioactivities, and has been applied in varied areas of vision science. However, designing, running, and interpreting screens requires careful planning to yield useful results. In this session, I will discuss some of these challenges and best practices for success, using examples of both target-based and cell-based screens from ophthalmic research.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.